Literature DB >> 9316739

Removal of endotoxin from recombinant protein preparations.

S Liu1, R Tobias, S McClure, G Styba, Q Shi, G Jackowski.   

Abstract

OBJECTIVES: To develop an effective method to remove endotoxin from large scale E. coli recombinant protein purifications. DESIGN AND METHODS: Triton X-114 phase separation, affinity chromatography utilizing immobilized polymyxin B or immobilized histidine, were used to remove endotoxin from purified preparations of recombinant CK-BB, CK-MB, CK-MM, myoglobin, and cardiac troponin I. Endotoxin levels were measured by a Limulus Amebocyte Lysate gel-clot assay. The immunoactivity of these protein preparations was determined by BIAcore analysis using a panel of in-house generated monoclonal antibodies and by a Stratus Fluorometric Analyzer. In the case of troponin I, the BIAcore was also utilized to measure troponin C interactions.
RESULTS: Phase separation with Triton X-114 was the most effective method in reducing the amount of endotoxin present in the protein preparations compared to either polymyxin B or histidine affinity chromatography. With Triton X-114, the reduction in endotoxin levels was greater than 99% and recovery of the proteins after endotoxin removal was greater than 90%. All three procedures for removing endotoxin had no deleterious effects on the immunoactivity of majority proteins when tested with a panel of monoclonal antibodies. Troponin I also retained its ability to bind to troponin C in the presence of Ca2+. Recombinant CK-BB and CK-MM which were expressed in the soluble fraction of E. coli cell lysates, contained significantly higher endotoxin levels than recombinant CK-MB, myoglobin and cardiac troponin I which were expressed in the form of inclusion bodies.
CONCLUSION: Of the three methods tested, Triton X-114 phase separation was the most effective way of removing endotoxin from recombinant proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316739     DOI: 10.1016/s0009-9120(97)00049-0

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  115 in total

1.  The hemoglobin receptor protein of porphyromonas gingivalis inhibits receptor activator NF-kappaB ligand-induced osteoclastogenesis from bone marrow macrophages.

Authors:  Yuji Fujimura; Hitoshi Hotokezaka; Naoya Ohara; Mariko Naito; Eiko Sakai; Mamiko Yoshimura; Yuka Narita; Hideki Kitaura; Noriaki Yoshida; Koji Nakayama
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Rv2468c, a novel Mycobacterium tuberculosis protein that costimulates human CD4+ T cells through VLA-5.

Authors:  Qing Li; Xuedong Ding; Jeremy J Thomas; Clifford V Harding; Nicole D Pecora; Assem G Ziady; Samuel Shank; W Henry Boom; Christina L Lancioni; Roxana E Rojas
Journal:  J Leukoc Biol       Date:  2011-12-07       Impact factor: 4.962

3.  Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier.

Authors:  Fiona J Radcliff; Jacelyn M S Loh; Birgit Ha; Diana Schuhbauer; James McCluskey; John D Fraser
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

Review 4.  Planning, evaluating and vetting receptor signaling studies to assess hyaluronan size-dependence and specificity.

Authors:  Paul H Weigel
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

5.  Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice.

Authors:  Yong Chul Kim; Yun Sik Choi; Jehan Alam; Yun-Ji Kim; Keum Jin Baek; Jaemoon Koh; Yeong Wook Song; Doo-Hyun Chung; Youngnim Choi
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

6.  SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE.

Authors:  A Zh Baltabekova; Zh S Shagyrova; A S Kamzina; M Voykov; Ye Zhiyenbay; E M Ramanculov; A V Shustov
Journal:  Mol Biotechnol       Date:  2015-08       Impact factor: 2.695

7.  Pig model mimicking chronic hepatitis E virus infection in immunocompromised patients to assess immune correlates during chronicity.

Authors:  Dianjun Cao; Qian M Cao; Sakthivel Subramaniam; Danielle M Yugo; C Lynn Heffron; Adam J Rogers; Scott P Kenney; Debin Tian; Shannon R Matzinger; Christopher Overend; Nicholas Catanzaro; Tanya LeRoith; Heng Wang; Pablo Piñeyro; Nicole Lindstrom; Sherrie Clark-Deener; Lijuan Yuan; Xiang-Jin Meng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

8.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

9.  Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties.

Authors:  Chao Wang; Veronique Beiss; Nicole F Steinmetz
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

10.  Helicobacter cinaedi cellulitis and bacteremia in immunocompetent hosts after orthopedic surgery.

Authors:  Toshio Kitamura; Yoshiaki Kawamura; Kiyofumi Ohkusu; Takayuki Masaki; Hirofumi Iwashita; Tomohiro Sawa; Shigemoto Fujii; Tatsuya Okamoto; Takaaki Akaike
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.